HUPO

Bioinformatics Technologies and Global Market Report, 2020-2023 Data and Projections of Compound Annual Growth Through 2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 22, 2024

The use of different tools manufactured by key players is likely to propel the growth of the bioinformatics market during the forecast period.

Key Points: 
  • The use of different tools manufactured by key players is likely to propel the growth of the bioinformatics market during the forecast period.
  • The scope of the study encompasses the global bioinformatics market based on geography, category and application.
  • It provides a detailed analysis of recent advances in omic technologies and examines their impact on the bioinformatics market.
  • In the market valuations, 2022 serves as the base year, while estimated values are provided for 2023 and forecast values for 2028.

Biognosys Presents Technological Innovations and Scientific Progress to Make the Proteome Actionable for Life Science Research at the HUPO 2023 World Congress

Retrieved on: 
Friday, September 15, 2023

Biognosys also will present ten posters showcasing technological innovations and novel scientific data with its proprietary proteomics research services, software, and kits.

Key Points: 
  • Biognosys also will present ten posters showcasing technological innovations and novel scientific data with its proprietary proteomics research services, software, and kits.
  • Biognosys’ team of scientific experts will be exhibiting and offering software demos at booth #408.
  • “Our continuously improving software and well-established kits empower users of major MS instruments to perform cutting-edge, hassle-free workflows for deep, high-throughput, reproducible proteomics research in-house.
  • At HUPO, Biognosys will present three posters highlighting powerful applications of Spectronaut 18 for comprehensive proteome quantification.

Quantum-Si Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Retrieved on: 
Monday, March 6, 2023

Selling, general and administrative expenses were $11.2 million in the fourth quarter of 2022, compared to $13.4 million in the fourth quarter of 2021.

Key Points: 
  • Selling, general and administrative expenses were $11.2 million in the fourth quarter of 2022, compared to $13.4 million in the fourth quarter of 2021.
  • Net loss was $33.1 million in the fourth quarter of 2022, compared to a net loss of $29.4 million in the fourth quarter of 2021.
  • Adjusted EBITDA was negative $24.5 million in the fourth quarter of 2022, compared to negative $20.4 million in the fourth quarter of 2021.
  • Quantum-Si will host a conference call to discuss its fourth quarter and fiscal year 2022 financial results on Monday, March 6, 2023, at 8:30 AM Eastern Time (ET).

Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Retrieved on: 
Thursday, February 23, 2023

SEATTLE, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2022.

Key Points: 
  • SEATTLE, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2022.
  • Reported Q4 2022 expenses below peak spending levels reached in Q4 of the prior year, helping to maintain cash runway well into 2025.
  • “We made good progress on key scientific and business objectives in 2022 despite challenging macroeconomic conditions,” said Sujal Patel, CEO of Nautilus.
  • Nautilus will host a conference call to discuss the fourth quarter and fiscal year 2022 financial results, business developments and outlook before market open on Thursday, February 23, 2023 at 5:30 AM Pacific Time / 8:30 AM Eastern Time.

Process Analytical Technology Market Size, Share & Trends Analysis Report 2022: A Global $5 Billion Market by 2030 - Digital Transformation in the Biopharma Industry Represents New Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, January 20, 2023

Process analytical technology is crucial to the manufacturing of pharmaceuticals as it provides data that aids in decision-making, quality assurance, product development, and factory implementation.

Key Points: 
  • Process analytical technology is crucial to the manufacturing of pharmaceuticals as it provides data that aids in decision-making, quality assurance, product development, and factory implementation.
  • Process analytical technology can detect contamination at levels as low as 0.1 parts per million, according to a report on the global process analytical technology.
  • This could result in considerable time and financial savings and further boost the adoption of analytical technology in bioprocessing.
  • It is anticipated that the adoption of new and better process analytical technology by key industry players will accelerate the expansion of the global market.

MOBILion Systems Demonstrates Integration of SLIM Technology with Orbitrap Technology Yielding Sensitivity Gains

Retrieved on: 
Wednesday, January 11, 2023

CHADDS FORD, Pa., Jan. 11, 2023 /PRNewswire/ -- MOBILion Systems, Inc., a life science tools and instrumentation company, presented at the Human Proteome Organization (HUPO) World Congress the first of its kind proof of concept integrating their SLIM (structures for lossless ion manipulation) technology with the Thermo Scientific™ Orbitrap Exploris™ 480 mass spectrometer.

Key Points: 
  • We are excited about the debut of this second iteration of SLIM technology to advance separation science.
  • A project involving MOBILion and Thermo Fisher aims to address the industry's current limitations in sensitivity, including challenges in detecting low abundance analytes.
  • MOBILion is proving its SLIM technology is a platform technology well-suited for customization, allowing it to be tuned to a variety of mass spectrometer platforms.
  • The early feedback from KOLs following the proof of concept integration with the Orbitrap platform has been overwhelmingly positive.

Biognosys Launches New Version of Spectronaut® at HUPO International Proteomics Congress

Retrieved on: 
Monday, December 5, 2022

Since its first release in 2003, Spectronaut has continuously improved and always supports the latest technologies in data acquisition.

Key Points: 
  • Since its first release in 2003, Spectronaut has continuously improved and always supports the latest technologies in data acquisition.
  • Spectronaut 17 is fully vendor-independent and compatible with proteomics data acquired on instruments of all major mass spectrometer providers.
  • At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that can dramatically improve human health.
  • Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research.

Bertis Announces Research Results of AI-based Disease Diagnosis Model in the World’s Largest Academic Event in Proteomics

Retrieved on: 
Thursday, December 8, 2022

Bertis , a proteomics-based precision medicine technology development company (CEOs Dong-young Noh, Seung-man Han), announced research results of AI-based disease diagnosis model, on December 8, 2022, at Human Proteome Organization 2022 (HUPO 2022), the worlds largest academic event in the field of proteomics1.

Key Points: 
  • Bertis , a proteomics-based precision medicine technology development company (CEOs Dong-young Noh, Seung-man Han), announced research results of AI-based disease diagnosis model, on December 8, 2022, at Human Proteome Organization 2022 (HUPO 2022), the worlds largest academic event in the field of proteomics1.
  • According to the results of its research, Bertis developed a diagnosis model that can determine the presence of a disease solely with proteomic mass spectrometry data by applying deep learning-based AI technology.
  • View the full release here: https://www.businesswire.com/news/home/20221208005409/en/
    Eric Y. Kim, Principal Machine Learning Engineer of Bertis Bioscience, is sharing the research results of a deep learning-based disease diagnosis model.
  • Bertis deep learning model uses only the proteomic spectrum to determine the existence of ovarian and pancreatic cancer with over 95% accuracy.

Quantum-Si Joins Human Proteome Organization (HUPO) Industrial Advisory Board

Retrieved on: 
Thursday, December 8, 2022

Quantum-Si Incorporated (Nasdaq: QSI) (Quantum-Si, QSI or the Company), The Protein Sequencing Company, today announced it has joined the Human Proteome Organization (HUPO) Industrial Advisory Board (IAB), an international scientific organization focused on fostering collaboration and promoting new technologies in the proteomics sphere.

Key Points: 
  • Quantum-Si Incorporated (Nasdaq: QSI) (Quantum-Si, QSI or the Company), The Protein Sequencing Company, today announced it has joined the Human Proteome Organization (HUPO) Industrial Advisory Board (IAB), an international scientific organization focused on fostering collaboration and promoting new technologies in the proteomics sphere.
  • HUPO supports a variety of international initiatives designed to illuminate the molecular features that dictate human health or disease, including the Human Proteome Project (HPP) , Initiative for Model Organism Proteomics (iMOP) , and Proteomic Standards Initiative (PSI) .
  • Quantum-Si is participating in the 21st HUPO World Congress, which is currently taking place in Cancun, Mexico, on December 4-8, 2022.
  • Founded in 2001, the Human Proteome Organization (HUPO) is a 501(c)(3) tax exempt non-profit organization registered in the state of New Mexico.

Nautilus Biotechnology Joins Human Proteome Organization (HUPO) Industrial Advisory Board

Retrieved on: 
Thursday, September 1, 2022

SEATTLE, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or Nautilus), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it has joined the Human Proteome Organization (HUPO) Industrial Advisory Board (IAB).

Key Points: 
  • SEATTLE, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or Nautilus), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it has joined the Human Proteome Organization (HUPO) Industrial Advisory Board (IAB).
  • The globally active committee supports academic and industrial leaders driving the development of innovative proteomics technologies and standards.
  • We are delighted to join the HUPO Industrial Advisory Board and to more broadly contribute to the proteomics community, said Parag Mallick, Ph.D., co-founder and Chief Scientist of Nautilus.
  • Nautilus mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine.